Our mission is to provide trustworthy and universal access to state-of-the-art total solutions to treat structural heart diseases

MicroPort CardioFlow adheres to the vision of building a people centric enterprise ranking as a global leader of evolving and emerging medical technologies

MicroPort CardioFlow Medtech Corporation(微创心通医疗科技有限公司)(the “Company”) is a medical device company in China focusing on research, development and commercialization of innovative transcatheter and surgical solutions for valvular heart diseases, which has several subsidiaries including Shanghai MicroPort CardioFlow Medtech Company Limited (collectively "MicroPort CardioFlow" or "the Group").
Our self-developed first-generation transcatheter aortic valve implantation (“TAVI”) product VitaFlow™ was approved by the NMPA in July 2019 and subsequently commercialized in China in August 2019. Our second generation product VitaFlow®II was approved by the NMPA in August 2021 in China, and is also under clinical trial in Europe. We plan to apply for the CE Mark of VitaFlow®II by the end of 2021.

VitaFlow® Aortic Valve System


On August 28, 2019, the first implantation of the self-developed VitaFlow® Aortic Valve System of MicroPort CardioFlow was performed at Zhongshan Hospital affiliated to Fudan University. Prof. Ge Junbo, Academician of Chinese Academy of Sciences, Director of the Cardiology Department of Zhongshan Hospital, performed the surgery and successfully implanted the VitaFlow® aortic valve into a 70-year-old male patient.



Clinical Solutions

Learn more


Aortic stenosis is one of the most common and serious valvular diseases. Transcatheter aortic valve implantation (TAVI) as a clinical interventional therapy, provides an ideal alternative treatment for critically ill patients with aortic stenosis who can not tolerate valve replacement through surgical means. With the increasing aging of the population and the expansion of the TAVI indications.


“Because Every Moment Matters”

CardioFlow Announces 2021 Interim Results

Shanghai, China — MicroPort CardioFlow Medtech Corporation, announced on August 29, 2021 the interim results of the company for the six months ended June 30, 2021. During the period, the company recorded revenue of RMB86.2 million, representing an increase of 121.8% as compared to the corresponding period of last year, with the gross profit margin increased significantly by 11 percentage points to 55.1%.


First “post-marketing” implantation in Western China for the TAVI procedure with VitaFlow® was performed by Professor Tao Lin on September 23, 2019

First “post-marketing” implantation in Western China for the TAVI procedure with VitaFlow® was performed at the Department of Cardiology of Xijing Hospital, the surgery was led by cardiology experts Professor Tao Lin and Professor Lifei.


VitaFlow® Transcatheter Aortic Valve System recieves market approval from NMPA

After being approved for the special approval procedure for innovative medical devices, the self-developed VitaFlow® Transcatheter Aortic Valve System (hereinafter referred to as “VitaFlow® Valve System”) of MicroPort CardioFlow successfully obtained the registration certificate from the National Medical Products Administration (NMPA) on July 12, 2019.


Join Us, to create a better tomorrow for more people across the globe